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BACKGROUND: According to a report from WHO, cases of rubella infection in Indonesia has increased up to 10-fold from 2007 to 2011. Despite 
no data of congenital rubella syndrome in the  report, there 
are approximately 45,000 cases of babies born with heart 
failure and 0.1-0.3% live births with congenital deafness 
in Indonesia. Allegedly, rubella infection during pregnancy 
may play a role in this condition. This study aimed to 
optimize and validate a real-time reverse transcriptase 
polymerase chain reaction (RT-qPCR) method to detect 
rubella virus RNA as an aid for the diagnosis of congenital 
rubella infection.
METHODS: Method optimization was conducted using 
nucleic acids extracted from Trimovax Merieux vaccine 
with the High Pure Viral Nucleic Acid Kit. One step RT-
qPCR was performed with Quantifast Multiplex RT-
PCR+R Kit. Target synthetic DNA was designed and used 
to determine the sensitivity of the method. RNA internal 
control was synthesized to control the process of extraction 
and amplification.
RESULTS: The analytical sensitivity of this method was 
as low as 5 copies target synthetic DNA/μl. The mean 
Coefficient of Variation (CV) % of the critical threshold (Ct) 
obtained were 2.71%, 1.20%, 1.62%, and 1.59% for within 
run, between run, between kit lots, and between operators, 
respectively. Recovery of the target synthetic DNA from 
amniotic fluid was 100.51% (by the log copies/μl) at the 
concentration of 105 copies/μl.
CONCLUSION: RT-qPCR is successfully used for the 
detection of rubella virus RNA in vaccine and synthetic 
LATAR BELAKANG: Menurut statistik dari WHO, kasus infeksi rubella di Indonesia telah meningkat hingga 10 kali lipat dari tahun 2007 
hingga 2011. Meskipun tidak ada laporan sindrom rubella 
bawaan dalam statistik, di Indonesia saat ini terdapat sekitar 
45.000 kasus bayi lahir dengan gagal jantung dan 0,1-
0,3% kelahiran hidup dengan ketulian kongenital. Infeksi 
rubella selama kehamilan diduga memainkan peran dalam 
kondisi ini. Penelitian ini bertujuan untuk mengoptimasi 
dan memvalidasi metode real-time reverse transcriptase 
polymerase chain reaction (RT-qPCR) untuk mendeteksi 
RNA virus rubella dalam diagnosis infeksi rubella bawaan.
METODE: Metode optimasi dilakukan dengan meng-
gunakan asam nukleat yang diekstrak dari Trimovax 
Merieux vaksin dengan High Pure Viral Nucleic Acid Kit. 
One-Step RT-qPCR dilakukan dengan Quantifast Multiplex 
RT-PCR+R Kit. DNA sintetis target dirancang dan 
digunakan untuk menentukan sensitivitas dari metode ini. 
Kontrol internal RNA disintesis untuk mengontrol proses 
transkripsi balik dan amplifikasi.
HASIL: Sensitivitas analitis dari metode ini adalah serendah 
5 kopi DNA sintetis target/μl. Rata-rata % Coefficient of 
Variation (CV) dari critical threshold (Ct) yang diperoleh 
berturut-turut adalah 2,71%, 1,20%, 1,62%, dan 1,59% 
untuk CV within run, between run, antar-kit, dan antar-
operator. Perolehan kembali DNA sintetis target dari cairan 
amnion adalah 100,51% (dalam jumlah log kopi/μl) pada 
konsentrasi 105 kopi/μl.
KESIMPULAN: RT-qPCR berhasil digunakan untuk 
mendeteksi RNA virus rubella dalam vaksin dan asam 
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Rubella virus (RV) infection is usually present as a mild, 
asymptomatic and self-limiting illness. However, primary 
RV infection during the first trimester of pregnancy leads 
to severe consequences, such as miscarriage, still birth 
and congenital rubella syndrome (CRS). Infants born with 
congenital rubella syndrome can suffer from deafness, 
blindness, heart defects, mental retardation, microcephaly 
and other serious health problems. Developmental and late-
onset abnormalities may occur due to the progress of CRS. 
(1-4) 
 In 2003 it was estimated that more than 100,000 
infants were born with CRS annually worldwide. CRS 
cases in American and European region have been 
reduced significantly through the vaccination program.
(5) Developing countries such as Indonesia which have 
not incorporated rubella-containing vaccines into routine 
national immunization programs have a great risk of RV 
transmission. Despite the relatively high risk of rubella 
infection in Indonesia, no data  are available on cases of 
CRS.(6) This is likely due to a lack of adequate prenatal 
and postnatal diagnosis to detect rubella infection during 
pregnancy and after delivery. 
 Prenatal diagnosis of RV infection is needed to 
prevent greater damage to the fetus. Meanwhile postnatal 
diagnosis is important to prevent further spread of the virus 
as the infants with congenital infection are likely to shed 
high concentrations of RV for long period. It is particularly 
important that pregnant women who are not rubella-immune 
not be exposed to infants with congenital rubella infection 
(3). 
 Currently the diagnosis of rubella infection during 
pregnancy in Indonesia is based only on the detection of 
rubella specific anti-IgM and IgG antibodies and their avidity 
of the mother. The results of these tests are not reliable for 
the diagnosis of rubella infection in the fetus because of a 
possibility of false positive IgM result (4). Rubella-specific 
nucleic acid. With its high sensitivity, good precision 
and recovery, this method offers a means to improve the 
diagnosis of congenital rubella infection in developing 
countries like Indonesia.
KEYWORDS: congenital rubella, RT-qPCR, prenatal 
diagnosis, amniotic fluid
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nukleat sintetis. Dengan sensitivitas yang tinggi, serta presisi 
dan perolehan kembali yang baik, metode ini menawarkan 
suatu cara untuk meningkatkan diagnosis infeksi rubella 
kongenital di negara-negara berkembang seperti Indonesia.
KATA KUNCI: rubella bawaan, RT-qPCR, diagnosis 
prenatal, cairan amnion
Method optimization was conducted using nucleic acids 
extracted from Trimovax Merieux vaccine (Sanofi Pasteur, 
Lyon, France). Target synthetic DNA was designed and used 
to determine the sensitivity and precision of the assay. RNA 
internal control oligonucleotide (RICO) was synthesized 
and used to control reverse transcription and amplification.
RNA extraction. RNA was extracted from 200 μl of 
Trimovax Merieux vaccine by using a High Pure Viral 
Nucleic Acid Kit (Roche, Mannheim, Germany), according 
to the manufacturer’s instructions.
RT-qPCR. One step RT-qPCR was performed with 
Quantifast Multiplex RT-PCR+R Kit (Qiagen, Hilden, 
Introduction
Methods
IgM may persist for months or years after infection or 
vaccination. Other than that there is a possibility that a fetus 
of infected woman is not infected by RV. Therefore a proper 
prenatal diagnosis using fetal sample is needed to prevent 
unnecessary termination of pregnancy.
 Ready-to-use real-time reverse transcriptase 
polymerase chain reaction (RT-qPCR) commercial kits 
are available for the detection of rubella RNA at various 
sample, however, such kits will require higher cost per test. 
Therefore, this study was conducted to produce a test with a 
lower cost.
 RV is a single-stranded RNA virus, thus its genome 
must be transcribed to cDNA before amplification (7-9). In 
this study, to allow reverse transcription and amplification 
in one tube, one-step RT-qPCR method was optimized to 
detect RV RNA. RNA internal control was synthesized 
to control both reverse transcription and amplification 
process. Internal controls are crucial for reliable results of 
a PCR process. Internal control amplification  is useful to 
distinguish whether a negative result is a true negative due 
to no pathogen in sample or false negative due to failure of 
the amplification reaction.
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was pure RNA and contain no residual control DNA. The 
amount of RICO to be used in the assay was determined.
Assessment of limit of detection. Limit of detection was 
determined by testing the dilution of target synthetic DNA. 
At first this assay was done in the absence of RICO and a 
total of approximately 9 replicates of the target synthetic 
DNA (10 copies/μl, 100 copies/μl, 1,000 copies/μl, 10,000 
copies/μl, and 100,000 copies/μl) were tested. The next 
trial was done for approximately 19 replicates of the lower 
concentrations (5 copies/μl, 10 copies/μl, and 100 copies/
μl). Lastly, the obtained limit of detection was tested in the 
present of RICO.
Assessment of Variability. The within-run precision was 
evaluated on 3 replicates for the low concentration (5 copies/
μl and 10 copies/μl) and high concentration (100,000 copies/
μl) target synthetic DNA within one run. Three experimental 
runs using the same reagent lot were performed by one 
operator on three different days to evaluate the between-
run precision. Variation between operators was assessed 
by two operators using the same samples. Both performed 
three different experimental runs using the same reagent 
lot. A total of two reagent lots were used for the lot-to-lot 
precision assessment. 
Spike recovery. Spike recovery test was done to determine 
the effect of the constituents of the sample on the results. 
Target synthetic DNA and vaccine was added into three 
tubes containing negative amniotic fluid (non-reactive by 
test for RV RNA) to the concentration of 5 copies/μl, 10 
copies/μl, and 100,000 copies/μl. Nucleic acid extraction 
and qPCR amplification were performed for all spiked 
amniotic fluid.
Results
One-step RT-qPCR was successfully performed to detect 
RV RNA, target synthetic DNA, and internal control. The 
specificity of the primers and probes was assessed using 
the Basic Local Alignment Search Tool (BLAST) from 
National Center for Biotechnology Information (NCBI) 
website. Primers and probes used in this study are listed in 
Table I. Primers specifically recognized a 185-nucleotide 
region of E1 gene in the genome of rubella Wistar RA 
27/3M strain. Trimovax Merieux vaccine contains not only 
vaccine strain of RV but also measles virus (Schwarz strain) 
and mumps virus (Urabe strain AM-9). Therefore during 
the nucleic acid extraction using High Pure Viral Nucleic 
Germany) to amplify a region in the E1 coding region and 
a 65-nucleotides RICO. Probe for RICO detection was 
designed based on potato cytochrome oxidase gene with 
modification. The 25 μl RT-PCR mixture was composed of 
2.5 μl of RNA template, 12.5 μl of 2x QuantiFast Multiplex 
RT-PCR Master Mix, 0.25 μl of QuantiFast RT Mix, 0.2 μM 
of forward (RV11) and reverse (RV12) primers, 0.1 μM of 
each probes, 2 μl of RICO, and 6.25 μl of RNase free water. 
The RT step was 20 min at 50°C and followed by PCR 
initial activation step at 95°C for 5 min. Amplification was 
done with 40 cycles of 95°C for 15 s and 60°C for 1 min. 
Negative control (nuclease free water) was included in each 
run. If negative control was contaminated, all results from 
the run were discarded.
Production of RICO. The designated synthetic DNA 
internal control oligonucleotide (ICO) contained a T7 RNA 
polymerase promoter sequence at the 5' end, followed by 
the binding region of target's primer flanking the probe-
binding regions as described in Figure 3. The ICO was 
dissolved and diluted to 5000 copies/μl. PCR amplification 
was conducted to obtain a double-stranded template for T7 
transcription. The amplification was performed in Veriti® 
96-Well Thermal Cycler (Applied Biosystem, USA) with 25 
μl reaction mixtures containing 5 μl of 10x PCR buffer, 0.2 
μM of T7 and RV12 primers, 5 μl of 5x GC rich solution, 2 
U of FastStart Taq DNA Polymerase, and 1 μl of ICO as the 
PCR template. The thermal cycling was carried out at 95°C 
for 4 min, 95°C for 30 s, followed by 40 cycles of 95°C for 
30 s, 60°C for 30 s, 72°C for 45 s, and one cycle of 72°C 
for 7 min. The PCR product was purified using High Pure 
PCR Product Purification Kit (Roche), and approximately 
50 ng of the PCR product (based on the measurements with 
Nanodrop (Thermo Scientific, Waltham, MA, USA) was 
transcribed with T7 RNA polymerase. The transcription 
mixture consisted of 2 μl of 10x transcription buffer, 0.5 μl of 
protector RNAse inhibitor (40 U/μl; Roche), 1 μl of T7 RNA 
polymerase (20 U/μl; Roche), 2 μl of of the ribonucleoside 
triphosphates mixture (containing 10 mM each of ATP, CTP, 
TTP, and GTP), and was added with water to the volume 
of 20 μl. The mixture was incubated at 37 °C for 2 h. The 
transcript was diluted 10-7 in RNase-free water. Purification 
of the diluted transcript was done by the digestion of 10 μl 
of diluted transcript with DNaseI in a total volume of 100 
μl that included 9 μl of DNAseI (18 U/μl; High Pure RNA 
Isolation Kit, Roche) and 81 μl of DNAse incubation buffer 
for 15 min at 25 °C. The mixture was incubated for 3 min at 
90 °C to stop the digestion and stored in aliquots at - 20 °C 
as RICO stock solution. The RICO stock solution was tested 
both with and without reverse transcriptase to verify that it 
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Name Role Sequence (5'-3') Length 
RV11 Forward primer CAACACGCCGCACGGACAAC 20 bp
RV12 Reverse primer CCACAAGCCGCGAGCAGTCA 20 bp
T7  T7 promoter primer CCAAGCTTCTAATACGACTCACTA 24 bp
Aber Probe Target probe FAM-AGGTCCAGGTCCCGCCCGAC-BHQ1 20 bp
COX-Probe Internal control probe HEX-TGCTTACGCTGGATGGAATGCCCGC-BHQ1 25 bp
ICO Internal control DNA CCAAGCTTCTAATACGACTCACTATAGGGAGACAACACGCCGCACGGACAACGCGGGCATTCCATCCAGCGTAAGCATGACTGCTCGCGGCTTGTGG 97 bp
Target 
Synthetic 
DNA
Synthetic external 
control
TTCTGCAACACGCCGCACGGACAACTCGAGGTCCAGGTCCCGCCCGACCCTGGGGACCT
GGTTGAGTACATTATGAACCACACCGGCAATCAGCAGTCCCGGTGGGGCCTCGGGAGCC
CGAATTGCCATGGCCCCGATTGGGCCTCCCCGGTTTGCCAACGCCATTCCCCTGACTGCT
CGCGGCTTGTGGGGGTC
195 bp
Table 1. Primer, probe, and controls DNA sequences.
Figure 1. Rubella RT-qPCR results on 2 % agarose gel stained with ethidium 
bromide. (A) RT-qPCR of vaccine extract. Lanes: M, molecular weight marker (100 
bp DNA ladder, Promega, USA); 1, negative control; 2, Trimovax Merieux vaccine 
extract. (B) RT-qPCR of target synthetic DNA and Trimovax Merieux vaccine 
extract in the presence of RICO. Lanes: M, molecular weight marker (O’RangeRuler 
10 bp DNA Ladder, ready-to-use, Fermentas, USA); 1, negative control, 2-7, target 
synthetic DNA (5; 10; 100; 1,000; 10,000; and 100,000 copies/μl), 8, Trimovax 
Merieux vaccine extract.   
!
Figure 2. Amplification curves of synthetic external control and RICO in Rotor-Gene Q software. Cycling A. Green (FAM)-No 
markers: amplification curve of target synthetic DNA; Cycling A. Yellow (HEX)-circles: amplification curve of RICO.
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Acid kit, RNA from those viruses can also be obtained. 
Even so, both viruses do not give positive results in this 
RT-qPCR system (Figure 1). Probes specific to target and 
internal control were successfully read by green and yellow 
channels of Rotor-Gene Q instrument (Figure 2).
 RICO was produced by the transcription of ICO as 
outlined in Figure 3. The purity of RICO was confirmed as no 
Figure 3. Production principal of RICO and 
design of target synthetic DNA. A: Rubella 
genome has 9,762 nucleotides and encodes 
two nonstructural polypeptides (p150 and p90) 
and three structural polypeptides (C, E2, and 
E1). T7 PP is a region for the recognition of T7 
RNA polymerase. RV11, COX, and RV12 are 
the target regions for the forward primer, COX 
probe (designed based on potato cytochrome 
oxidase gene sequence with modification) and 
reverse primer, respectively. B: Target synthetic 
DNA designed based on rubella E1 gene. Both 
ends are added with five nucleotides to enhance 
primer effectiveness. RV11, E1 part, and RV12 
will compose the 195 bp amplicon during the 
PCR process.
Mean Ct CV Mean Ct CV Mean Ct CV Mean Ct CV Mean Ct CV
5 34.16 2.71% 34.27 1.20% 34.04 1.62% 33.94 1.59% 33.99 1.59%
10 33.4 2.11% 33.08 1.74% 33.15 1.75% 33.14 1.97% 33.09 1.83%
100,000 19.21 0.65% 19.20 0.52% 19.19 0.44% 19.09 0.57% 19.13 0.65%
Total 
VariationCopy 
Number
Within Run 
Variation
Between Run 
Variation
Lot-to-lot 
Variation
Between Scientist 
Variation
E1 gene Internal Control
(FAM) (HEX)
100,000 19.13 38.11 0.5
10,000 22.59 35.74 0.63
1,000 26.1 35.84 0.73
100 29.66 34.79 0.85
10 33.09 35.48 0.93
5 33.99 35.43 0.96
Target Synthetic 
DNA Copy 
Number
Ct Ratio
Mean Ct Value
Table 2. Ct ratio between target synthetic DNA and RICO. 
Table 3. Precision of the test.
increase of fluorescence was seen in the absence of reverse 
transcriptase, as well as no band on the gel electrophoresis 
(data not shown). Primer competition between target 
synthetic DNA and RICO was indicated by a decrease in the 
ratio between Ct of RICO and Ct of target synthetic DNA at 
higher concentration of target synthetic DNA, as shown in 
Table 2. RICO amplification with target synthetic DNA was 
detectable in the presence of lower concentration of target 
synthetic DNA but not in the higher concentration.
 This PCR system could detect up to 5 copies/μl of target 
synthetic DNA. The precision of this assay was assessed 
by calculating the CV for the Ct values experimentally 
determined (Table 1). Experimental variability was higher 
in lower external control input. Within run variation 
contributed the largest CV for this assay.
 Spike recovery was performed to determine whether 
the RNA and DNA detection is affected by the difference 
between the diluent used to prepare the Trimovax vaccine 
or target synthetic DNA and the amniotic fluid matrix. The 
recovery of target synthetic DNA from amniotic fluid was 
almost 100%. The recovery of rubella RNA in Trimovax 
vaccine from amniotic fluid is not as good as the recovery 
of DNA in target synthetic DNA.
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RV is a teratogenic virus which is able to infect and cause 
damage to the fetus (1-5,7). One of several factors that 
influence the ability of viruses to cross the placenta is the 
mother’s immune status against the specific virus. In general, 
secondary infection and reinfection are less destructive than 
a primary infection as the mother has already developed 
immunity prior to the secondary infection (2). Primary and 
secondary infections can be distinguished by the laboratory 
testing of maternal immune status. In addition to the 
examination of the mother, it is important to look for the 
possibility of fetal infection and to assess the fetal damage 
and prognosis. For this purpose, prenatal laboratory testing 
is required so that clinical decisions such as drug treatment, 
termination of pregnancy or intrauterine IgG transfusion 
can be considered.
 Several methods can be used to assess viral infections 
in pregnancy. These methods can be divided into serology 
and virus detection. Virus detection is preferred over 
serological tests due to its ability to directly detect the 
presence of virus in samples. Virus detection can be done 
by virus isolation in tissue culture, direct antigen, shell-vial 
assay, RT-PCR, RT-nPCR, real-time PCR/RT-PCR, in situ 
hybridization, in situ PCR (2, 10). Although virus detection 
is used primarily for prenatal diagnosis, serological tests are 
still needed to support the results of virus detection and vice 
versa.
 Several groups have described molecular-based 
methods to detect rubella RNA from amniotic fluid and 
other samples. Bosma et al. performed reverse transcription 
nested PCR to detect rubella RNA from seven chorionic 
villus (CVS), three amniotic fluid (AF), and two fetal blood 
samples (11). Revello et al. used the same method but with 
different sets of primer to detect rubella RNA from nine AF, 
one CVS, and four fetal peripheral blood mononuclear cell 
(MN) samples (12). Two-step RT-PCR was used by Mace 
Discussion
AF + Excon AF + Excon AF + Excon
5 copies/µl 10 copies/µl 100,000 copies/µl
Copies 4 19 33 427,198
Log copies 1 1 2 6
Copies 6 20 40 400,000
Log copies 1 1 2 6
77.37 98.29 94.79 100.51
AF+ Trimovax
PCR 
Result
Teoritical 
Result
Recovery (%)
Table 4. Recovery of RNA and DNA from amniotic fluid.
et al. to detect rubella RNA in 110 AF and 23 fetal blood 
samples (13). On 2007, an investigation of rubella and 
congenital rubella syndrome was done using two block-
based RT-PCR and a two-step RT-qPCR (14).
 We adopted the one-step RT-qPCR described by 
Abernathy et al. to detect rubella RNA (15). One-step 
real-time RT-PCR was chosen in this study for its ability 
to enable reverse transcription, amplification, and detection 
of viral nucleic acids simultaneously in a single tube. This 
system reduces the possibility of contamination, simplifies 
work-flow, and enables faster testing. The use of probes in 
this system resulted in a more specific examination. It also 
allows quantification of viral nucleic acid. In the previous 
study, primer and probe used in this study had successfully 
detected rubella RNA from oral fluid and throat swabs. 
However, they have not been used to detect rubella RNA 
from amniotic fluid. In this study those primers and probe 
managed to detect rubella RNA from vaccine spiked in 
negative amniotic fluid.
 The limit detection of the test reported before was 12 
copies of RV RNA (15). Though we managed to obtain at 
least 5 copies synthetic DNA/μl, it was not comparable with 
the result from previous study as it was measured using 
DNA instead of RNA. Another study managed to detect 
2 copies of rubella cDNA using two-step RT-qPCR (14). 
This discrepancy could be caused by several factors, one of 
which was the size of the resulting amplicon. In that study, 
the resulting amplicon was 56 bp, which was much shorter 
than the amplicon size in our study. Another contributing 
factor was the usage of two-step RT-PCR that allowed 
them to optimize the reverse transcription step and increase 
the sensitivity of the assay. The specificity of the primers 
and probes was checked using the Basic Local Alignment 
Search Tool (BLAST) at http://www.ncbi.nlm.nih.gov/
BLAST. It was also confirmed by the PCR result on agarose 
gel and amplification curve. 
 Internal control is crucial to control the whole process, 
from extraction to amplification and detection . A competitive 
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RNA internal control has been introduced to monitor this 
assay system. It was able to distinguish negative results due 
to inhibition or human error from true-negative results. 
 DNA internal control can be used to monitor the 
amplification efficiency, but in RT-PCR it could not be used 
to control the reverse transcription efficiency. RNA internal 
control was used in this study, as it enabled the monitoring 
of reverse transcription efficiency and PCR efficiency. The 
reference publication of this study also used RNA internal 
control which is a 150-bp region of ß-actin gene (15). In 
their study, the target and internal control were amplified 
using a different primer set for each. The ß-actin gene was 
present in the specimen, thus this internal control was used 
to control the quality of RNA extraction as well. It was also 
expected to be able to control the reverse transcription step. 
However its ability to control the amplification efficiency 
was still questioned as it might not accurately reflect 
amplification of the primary target due to differences in the 
primer sets. 
 There are several approaches to the production of 
RNA internal control. The first approach is by using the 
normal cellular gene or housekeeping genes sequence (16-
17). This method will need different primers to amplify the 
internal control. The other approaches are by introducing 
a mutation to the target amplicon, deletion or insertion of 
sequences into the target amplicon, or splicing of the target 
primer sequences onto a nonhomologous DNA sequence 
(18-19). The RNA internal control was produced by 
modifying sequences between the recognition primer sites 
(20). First, we designed DNA sequence which contained 
a T7 RNA polymerase promoter sequence at the 5' end, 
followed by forward primer sequence, probe binding region, 
and the complementary sequence of reverse primer at the 
3' end. This double-stranded synthetic DNA was amplified 
and transcribed into RNA using T7 RNA polymerase. 
The produced RNA was purified in order to eliminate the 
remaining DNA. Using this approach the production of 
RNA internal control would be faster than the production 
of internal control within a plasmid. Though inserting the 
target sequence into plasmid could improve the stability of 
internal control, this approach consumes more production 
time as it needs cultivation of bacterial cells to multiply the 
plasmids and further steps to recover the plasmid and to 
produce the RNA internal control (19).
 Due to the competition between target and internal 
control for the primers, it is important to determine the 
optimal amount of internal control concentration in the 
assay. The addition of internal control could reduce the 
sensitivity of the assay therefore the amount of internal 
control in the assay should be as low as possible. Internal 
control concentration used in this study is the concentration 
at which internal control can be amplified in a reaction 
containing 5 copies/μl of DNA target synthetic DNA 
without disrupting the sensitivity of the assay. Agarose gel 
electrophoresis results indicate that internal control was 
still detected at a concentration of 10,000 copies of target 
synthetic DNA. The amplification curve of internal control 
was still detected at a concentration of 100,000 of target 
synthetic DNA. 
 The assay showed a good reproducibility with a total 
Ct coefficient of variation less than 3% for all parameters. 
Our result is comparable with the reproducibility which 
obtained by Zhau et al. who also used RT-qPCR to detect 
rubella RNA. This group used RV-specific PCR amplicon 
as a standard in their study. They obtained coefficient of 
variation range from 1.25 to 3.58% for 2.75×102 to 2.75×107 
copies/ml of standard (21). In our study the within run 
variation accounted the greatest variation among the other 
variations. Within run variation occurs likely due to error 
in dilution and pipetation. This means that the operator, 
run time, and lots different did not significantly affect the 
reproducibility of the assay. 
 The primers used in this study have not been used 
for rubella RNA detection in amniotic fluid. However, 
spike recovery was close to 100% in all of target synthetic 
DNA with various concentrations. This result indicated 
that amniotic fluid constituents did not interfere with the 
process of extraction, amplification and detection on the 
test. Although clinical sample was not available during this 
study, the good recovery result confirms the usefulness of 
this assay in clinical setting. The complexity of Trimovax 
Merieux vaccine content is suspected to be the cause of poor 
rubella RNA recovery from amniotic fluid. This vaccine is 
available in lyophilisates containing RNA genomes of three 
types of viruses in human albumin. 
 The design and result of this study demonstrate 
comparable performance between the assay of this study 
with the commercially available kit. Highly sensitive PCR 
assays, detecting 3–10 copies of RV RNA, are required 
for PD as fetal specimens generally contain low RV copy 
numbers (10). This assay managed to detect up to 5 copies 
synthetic DNA/μl. The RV11 and RV12 primer pairs were 
designed to amplify the E1 coding region. This is beneficial 
as other RT-qPCR protocols targeting the E1 gene have been 
used successfully for prenatal diagnosis (12, 13). Though 
the Rubella Real-TM Qual (Sacace Biotechnologies, Italy) 
can be used for rubella RNA qualitative detection in various 
samples including amniotic fluid and show a high sensitivity 
of not less than 400 copies/ml, this kit targeted p150 which 
is not a common gene target for rubella RNA detection (22). 
192
The Indonesian Biomedical Journal, Vol.5, No.3, December 2013, p.185-92 ISSN: 2085-3297
transcription-PCR. J Clin Microbiol. 1997; 35: 708-13.
13. Macé M, Cointe D, Six C, Levy-Bruhl D, du Châtelet IP, Ingrand D, et 
al. Diagnostic value of reverse transcription-PCR of amniotic fluid 
for prenatal diagnosis of congenital rubella infection in pregnant 
women with confirmed primary rubella infection. J Clin Microbiol. 
2004; 42: 4818-20.
14. Jin L, Thomas B. Application of molecular and serological assays 
to case based investigations of rubella and congenital rubella 
syndrome. J Med Virol. 2007; 79; 1017-24.
15. Abernathy E, Cabezas C, Sun H, Zheng Q, Chen MH, Castillo-
Solorzano C, et al. Confirmation of rubella within 4 days of rash 
onset: comparison of rubella virus RNA detection in oral fluid 
with immunoglobulin M detection in serum or oral fluid. J Clin 
Microbiol. 2009; 47: 182-88.
16. Rosenstraus M, Wang Z, Chang SY, DeBonville D, Spadoro JP. An 
internal control for routine diagnostic PCR: design, properties, and 
effect on clinical performance. J Clin Microbiol. 1998; 36: 191-97.
17. Jain M, Nijhawan A, Tyagi AK, Khurana JP. Validation of housekeeping 
genes as internal control for studying gene expression in rice by 
quantitative real-time PCR. Biochem Biophys Res Commun. 2006; 
345: 646-51.
18. Gibson UE, Heid CA, Williams PM. A novel method for real time 
quantitative RT-PCR. Genome Res. 1996; 6: 995-1001.
19. Hoorfar J, Malorny B, Abdulmawjood A, Cook N, Wagner M, Fach P. 
Practical considerations in design of internal amplification controls 
for diagnostic PCR assays. J Clin Microbiol. 2004; 42: 1863-68.
20. Burggraf S, Olgemöller B. Straightforward procedure for internal 
control of real-time reverse transcription amplification assays. Clin 
Chem. 2005; 51: 1508-10.
21. Zhao LH, Ma YY, Wang H, Zhao SP, Zhao WM, Li H, et al. 
Establishment and application of a TaqMan real-time quantitative 
reverse transcription-polymerase chain reaction assay for rubella 
virus RNA. Acta Biochim Biophys Sin (Shanghai). 2006; 38: 731-6.
22. Sacace Biotechnologies. Rubella Real-TM Qual Handbook. 2011. 
DNA GDANSK 2011; [updated 2011 Nov 11; cited 2014 May 26]. 
Available from: http://www.dnagdansk.com/.
23. Liferiver. Rubella Virus Real Time RT-PCR Kit User Manual. Bio SB 
2012; [updated 2012 Jul 1; cited 2014 May 26]. Available from: 
http://www.biosb.com/.
Conclusion
References
RT-qPCR is successfully used for the detection of RV 
RNA in vaccine and synthetic nucleic acid. One-step RT-
PCR system eliminates manual reverse transcription thus 
simplify and accelerate detection method. With its high 
sensitivity, good precision and recovery, this method offers 
as a  means to improve the diagnosis of congenital rubella 
infection in developing countries like Indonesia.
1. Webster WS. Teratogen update: congenital rubella. Teratology. 1998; 58: 
13-23.
2. Mendelson E, Aboudy Y, Smetana Z, Tepperberg M, Grossman 
Z. Laboratory assessment and diagnosis of congenital viral 
infections: rubella, cytomegalovirus (CMV), varicella-zoster virus 
(VZV), herpes simplex virus (HSV), parvovirus B19 and human 
immunodeficiency virus (HIV). Reprod Toxicol. 2006; 21: 350-82.
3. Saraswathy TS, Rozainanee MZ, Asshikin RN, Zainah S. Congenital 
rubella syndrome: a review of laboratory data from 2002 to 2011. 
Southeast Asian J Trop Med Public Health. 2013; 44: 429-35.
4. Best JM. Rubella. Semin Fetal and Neonatal Med. 2007; 12: 182-92.
5. Robertson SE, Featherstone DA, Gacic-Dobo M, Hersh BS. Rubella 
and congenital rubella syndrome: global update. Rev panam Salud 
Publica. 2003; 14: 306-15. 
6. World   Health   Organization.   WHO  vaccine-preventable  diseases: 
monitoring system. 2013 global summary; 2013 [updated 2013 Oct 
20; cited 2013 Des 13]. Available from: http://apps.who.int/.
7. Banatvala JE, Brown DW. Rubella. Lancet. 2004; 363: 1127-37.
8. Chen MH, Icenogle J. Molecular virology of rubella virus. In: Banatvala 
JE, Peckham C, editors. Perspectives in medical virology, Vol. 15. 
Rubella viruses. Amsterdam: Elsevier; 2007. p.19-37.
9. World Health Organization. Weekly epidemiological record: July 2011. 
WHO 2011; 86: 301-16. Available from: http://www.who.int/
wer/2011/wer8629.pdf
10. Best JM, Enders G. Laboratory diagnosis of rubella and congenital 
rubella. In: Banatvala JE, Peckham C, editors. Perspectives in 
medical virology, Vol. 15. Rubella viruses. Amsterdam: Elsevier; 
2007. p.39-77.
11. Bosma TJ, Corbett KM, Eckstein MB, O'Shea S, Vijayalakshmi P, 
Banatvala, et al. Use of PCR for prenatal and postnatal diagnosis of 
congenital rubella. J Clin Microbiol. 1995; 33: 2881-87.
12. Revello MG, Baldanti F, Sarasini A, Zavattoni M, Torsellini M, Gerna 
G. Prenatal diagnosis of rubella virus infection by direct detection 
and semiquantitation of viral RNA in clinical samples by reverse 
Another kit from Shanghai ZJ Bio-Tech Co., Ltd., known as 
Rubella Virus Real Time RT-PCR Kit (Liferiver, China) also 
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